ZNTL — Zentalis Pharmaceuticals Llc
NASDAQ · Healthcare · Biotechnology
$3.79
+$0.08 (+2.29%)
Zentalis Pharmaceuticals Llc (ZNTL) is a biotechnology company listed on NASDAQ. It is led by Julie M. Eastland M.B.A., based in 10275 Science Center Dr., San Diego, CA, United States, 92121, with about 106 employees. Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers in the United States. It develops azenosertib, which is in a Phase 3 clinical trial for the treatment of ovarian cancer and other tumor types. The company also develops ZN-c3-001, a phase 1 study that evaluated azenosertib monotherapy in solid tumors; and MAMMOTH (ZN-c3-006) is a Phase 1/2 clinical trial of azenosertib in patients with PARP-inhibitor resistant ovarian cancer. It has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC. Zentalis Pharmaceuticals, Inc. was incorporated in 2014 and is based in San Diego, California.
Latest reported ZNTL revenue for 2025-09-30 was $0. Net income was -$26.7M. ZNTL currently screens at market cap $257.7M.
Use this ZNTL page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the ZNTL quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the ZNTL SEC filings page. Lician reads the product cache first so this HTML stays unique to Zentalis Pharmaceuticals Llc even when a live quote feed is slow.
About Zentalis Pharmaceuticals Llc
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers in the United States. It develops azenosertib, which is in a Phase 3 clinical trial for the treatment of ovarian cancer and other tumor types. The company also develops ZN-c3-001, a phase 1 study that evaluated azenosertib monotherapy in solid tumors; and MAMMOTH (ZN-c3-006) is a Phase 1/2 clinical trial of azenosertib in patients with PARP-inhibitor resistant ovarian cancer. It has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC. Zentalis Pharmaceuticals, Inc. was incorporated in 2014 and is based in San Diego, California.
ZNTL Key Statistics
Market Cap
$257.69M
Volume
576,203
Previous Close
$3.88
Day Range
$3.83 – $3.93
P/B Ratio
1.41
EPS
-$2.33
Revenue
$67.42M
Net Income
-$165.87M
Gross Profit
$0.00
Free Cash Flow
$0.00
Profit Margin
-246.0%
Employees
106
ZNTL Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $67.42M | $0.00 | $0.00 | $0.00 |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$165.87M | -$292.31M | -$237.11M | -$50.09M |
| EPS (Diluted) | -$2.33 | -$4.47 | -$4.48 | -$1.11 |
Total Assets
$430.34M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$33.90M
Operating Cash Flow
-$170.86M
Free Cash Flow
$0.00
Zentalis Pharmaceuticals Llc Company Information
- CEO, President & Director
- Julie M. Eastland M.B.A.
- Headquarters
- 10275 Science Center Dr., San Diego, CA, United States, 92121
- Website
- zentalis.com
- Phone
- 858 263 4333
- IPO / Founded
- 2020-04-03
- Sector
- Healthcare
- Industry
- Biotechnology